Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Keros Therapeutics (KROS) Tax Provisions (2020 - 2025)

Keros Therapeutics filings provide 4 years of Tax Provisions readings, the most recent being -$1.5 million for Q4 2025.

  • On a quarterly basis, Tax Provisions fell 604.67% to -$1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.9 million, a 1527.67% increase, with the full-year FY2025 number at $4.9 million, up 1527.67% from a year prior.
  • Tax Provisions hit -$1.5 million in Q4 2025 for Keros Therapeutics, down from -$1.4 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $10.0 million in Q1 2025 to a low of -$2.2 million in Q2 2025.
  • Median Tax Provisions over the past 3 years was $6000.0 (2021), compared with a mean of $899250.0.
  • Biggest five-year swings in Tax Provisions: skyrocketed 129.07% in 2021 and later crashed 604.67% in 2025.
  • Keros Therapeutics' Tax Provisions stood at $2.0 million in 2021, then plummeted by 84.99% to $300000.0 in 2024, then crashed by 604.67% to -$1.5 million in 2025.
  • The last three reported values for Tax Provisions were -$1.5 million (Q4 2025), -$1.4 million (Q3 2025), and -$2.2 million (Q2 2025) per Business Quant data.